The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells

Bernengo, Maria Grazia; Novelli, Mauro; Quaglino, Pietro; Lisa, Francesco; Matteis, A. De; Savoia, Paola; Cappello, N.; Fierro, Maria Teresa

doi:10.1046/j.1365-2133.2001.04014.x

Cited by 189 publications

(159 citation statements)

References 40 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…vious reports on peripheral blood involvement by CTCL (2)(3)(4)(5)(6)15). We concur with the conclusions of the authors of several previous studies, that alterations in CD26 expression are most significant when combined with aberrant expression levels of other T-cell antigens (3,4,(15)(16)(17).…”

Section: Cd26 Expression In T Cells In Tissues and Body Fluidssupporting

confidence: 80%

See 1 more Smart Citation

Utility of CD26 in flow cytometric immunophenotyping of T‐cell lymphomas in tissue and body fluid specimens

Pierson

Jones

Muzzafar³

et al. 2008

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: CD26 is expressed by most CD41 T cells in normal peripheral blood specimens. Neoplastic T cells are frequently CD262 in mycosis fungoides/Sezary syndrome involving the peripheral blood. However, CD26 expression by reactive and neoplastic T cells in solid tissues and body fluids has not been fully characterized by flow cytometry (FC).Methods: Solid tissue and body fluid specimens were assayed for CD26 expression using four-color FC immunophenotyping, by qualitative assessment of population clusters, and by quantitation with comparison with isotype controls. Benign T cells were studied in reactive tissues and in the background of other malignancies.Results: Many T-cell lymphomas were dim or negative for CD26, whereas a few were brightly positive. In the majority of T-cell lymphomas, CD26 expression could potentially help identify aberrant population clusters. T cells in reactive tissue specimens and tumor-infiltrating T cells were commonly dim to negative for CD26.Conclusions: Both T-cell lymphomas and reactive T cells in tissue and body fluid specimens often show low levels of CD26 expression. Therefore, quantitative methods may not reliably distinguish benign from neoplastic T cells in these specimens. However, CD26, in combination with other T-cell markers, can be helpful for identifying aberrant population clusters in T-cell lymphomas. q 2008 Clinical Cytometry

show abstract

Section: Cd26 Expression In T Cells In Tissues and Body Fluidssupporting

confidence: 80%

“…mycosis fungoides and Sezary syndrome [MF/ SS]), the neoplastic cells are CD41 and negative for CD26 (2)(3)(4). Several publications have emphasized quantitation of the CD41CD262 subset of T cells in the peripheral blood in the diagnosis and followup of MF/SS (2,5,6).…”

mentioning

confidence: 99%

Utility of CD26 in flow cytometric immunophenotyping of T‐cell lymphomas in tissue and body fluid specimens

Pierson

Jones

Muzzafar³

et al. 2008

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…As previously described (11), CD10 þ T-cells were observed in cases of PTCL and AIL, while cd T-cell receptor was expressed in the two hepatosplenic T-cell lymphomas. FC demonstrated altered T-cell phenotype CD3 þdim CD4 þ CD26 À in all cases of mycosis fungoides/ Sézary syndrome (MF/SS) (16). In ALCL, the CD30 antigen was positive in all cases of ALK þ and in most cases of ALK À .…”

Section: Mature T-and Nk-cell Neoplasmsmentioning

confidence: 94%

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Demurtas

Stacchini

Aliberti

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

“…7,10 In the past decade, flow cytometric immunophenotyping has proven to be more reliable than morphologic examination in assessing for lymphoma (also known as Sézary) cells in peripheral blood of mycosis fungoides and Sézary syndrome patients, as the neoplastic cells often have an aberrant immunophenotype. [11][12][13][14][15][16] However, it has been recognized that T-cell antigenic alterations are not entirely specific for mycosis fungoides or Sézary syndrome, and have been observed in some reactive conditions. 11,17,18 Assessment of T-cell clonality using molecular methods is therefore recommended by the International Society for Cutaneous Lymphomas, even in the presence of flow cytometric immunophenotypic aberrancies.…”

mentioning

confidence: 99%

“…[11][12][13][14][15][16] However, it has been recognized that T-cell antigenic alterations are not entirely specific for mycosis fungoides or Sézary syndrome, and have been observed in some reactive conditions. 11,17,18 Assessment of T-cell clonality using molecular methods is therefore recommended by the International Society for Cutaneous Lymphomas, even in the presence of flow cytometric immunophenotypic aberrancies.…”

mentioning

confidence: 99%

Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vβ chain antibodies and its application in blood staging

et al. 2010

View full text Add to dashboard Cite

Peripheral blood involvement has been recognized as an adverse prognostic factor in patients with mycosis fungoides and Sé zary syndrome. However, accurate identification and enumeration of the neoplastic cells in these diseases can be challenging. We assessed the clinical utility of flow cytometric immunophenotypic analysis of T-cell receptor Vb expression in 82 mycosis fungoides and 6 Sé zary syndrome patients, with an atypical T-cell immunophenotype, or abnormal CD4:CD8 ratio, identified from peripheral blood specimens of 723 patients submitted for routine mycosis fungoides/Sé zary syndrome blood staging. To improve detection sensitivity, Vb expression was analyzed on gated CD3 þ CD4 þ T cells or T cells with an aberrant immunophenotype, if present. The flow cytometric results were compared with traditional morphologic assessment (n ¼ 88) and molecular methods to assess the T-cell receptor c or b genes (n ¼ 41 tested in parallel). Flow cytometric immunophenotyping yielded a clonal Vb pattern in 60/82 mycosis fungoides and 6/6 Sé zary syndrome patients. By contrast, flow cytometric Vb was negative in all 10 healthy donors and 18 control patients, showing a specificity of 100% and concordance with molecular testing of 86%. Using flow cytometric Vb results instead of morphologic assessment, 12 patients were upstaged from B1 to B2, and 20 patients from B0 to B1 (Po0.0001). The 12 upstaged B2 patients had no morphologic evidence of involvement, but had an aggressive clinical course similar to those staged by traditional morphologic assessment (median survival 27 vs 41 months, log-rank P ¼ 0.701). In 30/44 patients with a tumor-associated Vb expression, a single Vb tube was used to monitor treatment response. In conclusion, flow cytometric Vb analysis is rapid and convenient, can assess T-cell clonality and tumor quantity simultaneously, and is useful both in initial blood staging and monitoring tumor burden during therapy in patients with mycosis fungoides or Sé zary syndrome.

show abstract

The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells

Abstract: We feel that a CD4+ CD26- percentage value higher than 30% of peripheral blood lymphocytes could correctly identify the presence of peripheral blood involvement in SS and MF patients.

Cited by 189 publications

References 40 publications

Utility of CD26 in flow cytometric immunophenotyping of T‐cell lymphomas in tissue and body fluid specimens

Utility of CD26 in flow cytometric immunophenotyping of T‐cell lymphomas in tissue and body fluid specimens

Tissue flow cytometry immunophenotyping in the diagnosis and classification of non‐Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases

Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vβ chain antibodies and its application in blood staging

Contact Info

Product

Resources

About